Abstract 5760
Background
PD-L1 expression was approved by U.S. FDA as companion or complementary diagnostic for most anti-PD-1/ PD-L1 inhibitors, which is well accepted as one of the important biomarkers in the selection of patients who would have high potential to respond. By far, the PD-L1 prevalence in Chinese solid tumor patients is poorly reported. In lung cancer, the correlation between PD-L1 expression and another important biomarker tumor mutation burden (TMB) has been demonstrated to be weak, however, the results in other types of solid tumor are still limited, which needs further explorations.
Methods
A total of 6,571 Chinese solid tumor patients, including 1,534 lung cancer patients and 5,037 other solid tumor patients, from 70 sites were studied. The tissue samples, either surgical resection specimens or biopsy samples, were both stained by clinical validated PD-L1 IHC assay and performed the next generation sequencing (NGS) using a validated commercial 381-cancer-gene panel, with panel size over 0.5 MB. TMB was calculated according to NGS results.
Results
835 of 1534 (54.4%) lung cancer patients had PD-L1 expression >1% on tumor cells. The PD-L1 prevalence in NSCLC, small cell lung cancer, squamous cell carcinoma, adenocarcinoma and adenosine squamous cell carcinoma were 55.4%, 16.1%, 64.2%, 52.7% and 66.7%, respectively. Among 5,037 non-lung solid tumor patients, the proportion of PD-L1 expression >1% is 28.4%, 23.5%, 38.9%, 29.5%, 60% and 37.1% in gastric cancer, colorectal cancer, hepatobiliary cancer, urologic cancer, head and neck cancer and gynecological cancer. The average TMB of PD-L1 expression >1% solid tumor patients (excluding lung cancer) was 10.87/ MB, which is statistically significant higher than PD-L1 expression <1% subgroup (8.64/MB, p = 2.5e-06).
Conclusions
The PD-L1 prevalence varied in different tumor type subgroups. And TMB was significant different between PD-L1 expression >1% and <1% subgroups. But, the correlation between PD-L1 and TMB needs more studies, which is important to reveal whether these two biomarkers are mutually independent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
3D Medicine, Shanghai.
Funding
3D Medicine, Shanghai.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract